Quick Answer
REVIVA PHARMACEUTICALS HOLDINGS, INC. reported R&D Expense of $11.71 million for fiscal year 2025.
REVIVA PHARMACEUTICALS HOLDINGS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $11.71M | -48.9% |
| 2024 | $22.91M | -27.1% |
| 2023 | $31.42M | +37.4% |
| 2022 | $22.87M | +371.4% |
| 2021 | $4.85M | +0.0% |
| 2021 | $4.85M | +1543.8% |
| 2020 | $295.1K | +50.8% |
| 2019 | $195.7K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.13M | -68.9% | -42.8% |
| June 30, 2025 | $3.72M | -33.3% | -9.5% |
| March 31, 2025 | $4.11M | -28.9% | -40.0% |
| September 30, 2024 | $6.86M | -28.4% | +22.8% |
| June 30, 2024 | $5.58M | -32.4% | -3.4% |
| March 31, 2024 | $5.78M | +5.5% | -39.6% |
| September 30, 2023 | $9.57M | +315.1% | +15.9% |
| June 30, 2023 | $8.26M | +82.9% | +50.5% |
- REVIVA PHARMACEUTICALS HOLDINGS, INC. showed a decrease of -48.9% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, REVIVA PHARMACEUTICALS HOLDINGS, INC.’s r&d expense has grown by 5881.7% (from $195.7 thousand to $11.71 million).
- The most recent figure is from REVIVA PHARMACEUTICALS HOLDINGS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: